» Articles » PMID: 33677435

Association of Obesity with Cardiovascular Risk Factors and Kidney Disease Outcomes in Primary Proteinuric Glomerulopathies

Abstract

Background/aims: Obesity is a known risk factor for cardiovascular disease and contributes to the development and progression of kidney disease. However, the specific influence of obesity on outcomes in primary glomerular disease has not been well characterized.

Methods: In this prospective cohort study, data were from 541 participants enrolled in the Nephrotic Syndrome Study Network (NEPTUNE), between 2010 and 2019, at 23 sites across North America. Blood pressure, lipids, and kidney disease outcomes including complete proteinuria remission, kidney failure, and chronic kidney disease progression were evaluated. Data were analyzed using linear and logistic regression with generalized estimating equations and time-varying Cox regression with Kaplan-Meier plots.

Results: The prevalence of obesity at baseline was 43.3% (N = 156) in adults and 37.6% (N = 68) in children. In adults, obesity was longitudinally associated with higher systolic BP (β = 6.49, 95% CI: 2.41, 10.56, p = 0.002), dyslipidemia (OR = 1.74, 95% CI: 1.30, 2.32, p < 0.001), triglycerides (β = 41.92, 95% CI: 17.12, 66.71, p = 0.001), and lower HDL (β = -6.92, 95% CI: -9.32, -4.51, p < 0.001). In children, obesity over time was associated with higher systolic BP index (β = 0.04, 95% CI: 0.02, 0.06, p < 0.001) and hypertension (OR = 1.43, 95% CI: 1.04, 1.98, p = 0.03). In both adults and children, obesity was associated with a significantly lower hazard of achieving complete remission of proteinuria (adult HR = 0.80, 95% CI: 0.69, 0.88, p < 0.001; pediatric HR = 0.72, 95% CI: 0.61, 0.84, p < 0.001).

Conclusion: Obesity was associated with higher cardiovascular risk and less proteinuria remission from nephrotic syndrome in adults and children with proteinuric glomerulopathies. Weight-loss strategies may forestall cardiovascular disease and progressive kidney function decline in this high-risk patient group.

Citing Articles

Association of Obesity With Kidney and Cardiac Outcomes Among Patients With Glomerular Disease: Findings From the Cure Glomerulonephropathy Network.

Zeitler E, Glenn D, Hu Y, Falk R, Hogan S, Mottl A Am J Kidney Dis. 2024; 84(3):306-319.e1.

PMID: 38750877 PMC: 11344669. DOI: 10.1053/j.ajkd.2024.03.020.


Cardiovascular Risk in Patients With Glomerular Disease: A Narrative Review of the Epidemiology, Mechanisms, Management, and Patient Priorities.

Myette R, Lamarche C, Odutayo A, Verdin N, Canney M Can J Kidney Health Dis. 2024; 11:20543581241232472.

PMID: 38404647 PMC: 10894549. DOI: 10.1177/20543581241232472.


Pediatric contributions and lessons learned from the NEPTUNE cohort study.

Modi Z, Zhai Y, Yee J, Desmond H, Hao W, Sampson M Pediatr Nephrol. 2024; 39(9):2555-2568.

PMID: 38233720 DOI: 10.1007/s00467-023-06256-7.


Antihyperglycemic activity of 14-deoxy, 11, 12-didehydro andrographolide on streptozotocin-nicotinamide induced type 2 diabetic rats.

Kamaraj N, Velumani K, Guru A, Issac P Mol Biol Rep. 2023; 50(12):9875-9886.

PMID: 37856062 DOI: 10.1007/s11033-023-08878-4.


A lack of KDIGO guidelines for adolescents and young adults with IgA nephropathy.

Dixon A, Blanchette E, Kendrick J Pediatr Nephrol. 2023; 39(1):297-304.

PMID: 37261517 DOI: 10.1007/s00467-023-06027-4.


References
1.
Sethna C, Ng D, Jiang S, Saland J, Warady B, Furth S . Cardiovascular disease risk among children with focal segmental glomerulosclerosis: a report from the chronic kidney disease in children study. Pediatr Nephrol. 2019; 34(8):1403-1412. PMC: 6594397. DOI: 10.1007/s00467-019-04229-3. View

2.
Tobar A, Ori Y, Benchetrit S, Milo G, Herman-Edelstein M, Zingerman B . Proximal tubular hypertrophy and enlarged glomerular and proximal tubular urinary space in obese subjects with proteinuria. PLoS One. 2013; 8(9):e75547. PMC: 3783420. DOI: 10.1371/journal.pone.0075547. View

3.
Tsuboi N, Okabayashi Y, Shimizu A, Yokoo T . The Renal Pathology of Obesity. Kidney Int Rep. 2017; 2(2):251-260. PMC: 5678647. DOI: 10.1016/j.ekir.2017.01.007. View

4.
Tsuboi N, Utsunomiya Y, Hosoya T . Obesity-related glomerulopathy and the nephron complement. Nephrol Dial Transplant. 2013; 28 Suppl 4:iv108-13. DOI: 10.1093/ndt/gft258. View

5.
Yonekura Y, Goto S, Sugiyama H, Kitamura H, Yokoyama H, Nishi S . The influences of larger physical constitutions including obesity on the amount of urine protein excretion in primary glomerulonephritis: research of the Japan Renal Biopsy Registry. Clin Exp Nephrol. 2014; 19(3):359-70. DOI: 10.1007/s10157-014-0993-y. View